There are 2789 resources available
606P - Role of serum biomarkers of bone metabolism in metastatic castration-resistance prostate cancer (mCRPC) patients (pts) treated with radium-223 (Ra223): PRORADIUM study final results
Presenter: Nuria Romero Laorden
Session: ePoster Display
607P - Impact of docetaxel on quality of life (QoL) in elderly and non-elderly metastatic castration-resistant prostate cancer (mCRPC) patients (Pts)
Presenter: Silvia Rubio-Novella
Session: ePoster Display
648TiP - PSMAfore: A phase III study to compare <sup>177</sup>Lu-PSMA-617 treatment with a change in androgen receptor pathway inhibitor in taxane-naïve patients with mCRPC
Presenter: Michael Morris
Session: ePoster Display
649TiP - PRIMORDIUM: A randomized, international, trial-in-progress of adding apalutamide to radiotherapy and an LHRH agonist in high-risk patients with PSMA-PET-positive hormone-sensitive prostate cancer
Presenter: Boris Hadaschik
Session: ePoster Display
650TiP - PARADIGM: Plasma analysis for response assessment and to direct the management of metastatic prostate cancer (mPCa)
Presenter: Anuradha Jayaram
Session: ePoster Display
660P - Phase III CLEAR trial in advanced renal cell carcinoma (aRCC): Outcomes in subgroups and toxicity update
Presenter: Toni Choueiri
Session: ePoster Display
661P - Conditional survival and 5-year follow-up in CheckMate 214: First-line nivolumab + ipilimumab (N+I) versus sunitinib (S) in advanced renal cell carcinoma (aRCC)
Presenter: Robert Motzer
Session: ePoster Display
583P - Baseline plasma tumour DNA (ptDNA) correlates with PSA kinetics in metastatic castration-resistant prostate cancer (mCRPC) treated with abiraterone or enzalutamide
Presenter: Vincenza Conteduca
Session: ePoster Display
584P - Health-related quality of life (HRQoL) in ACIS: A phase III trial of apalutamide with abiraterone acetate and prednisone (APA + AAP) vs AAP in metastatic castration-resistant prostate cancer (mCRPC)
Presenter: Stephane Oudard
Session: ePoster Display
585P - Safety analysis of the phase III IPATential150 trial of ipatasertib (ipat) plus abiraterone (abi) in patients with metastatic castration-resistant prostate cancer (mCRPC)
Presenter: Cora Sternberg
Session: ePoster Display